| 31. |
- Luoma, ML, et al.
(författare)
-
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
- 2003
-
Ingår i: European Journal of Cancer. - 1879-0852 .- 0959-8049. ; 39:10, s. 1370-1376
-
Tidskriftsartikel (refereegranskat)abstract
- The purpose of the study was to investigate whether baseline quality of life (QoL) and changes in QoL scores from baseline are prognostic for time to progression (TTP) and/or overall survival (OS) in patients with advanced breast cancer receiving docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). QoL was assessed at baseline and before each treatment using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). Survival curves and probabilities were estimated using the Kaplan-Meier technique. The Cox proportional hazards regression model was used for both the univariate and multivariate analyses to explore relationships between baseline QoL variables and TTP, as well as OS. In the univariate analysis, more severe pain and fatigue at baseline were predictive for a shorter OS; global QoL, physical functioning and appetite loss had a borderline significance (P=0.0130 for global QoL; P=0.0256 for physical functioning: P=0.0149 for appetite loss). World Health Organization (WHO) performance status was significantly predictive for OS. In the multivariate analysis, more severe pain at baseline was predictive for a shorter OS. In contrast, baseline QoL had no prognostic value for the duration of TTP. QoL change scores from baseline QoL predicted neither OS nor TTP. Our findings suggest that while QoL measurements are important in evaluating patients' QoL, they have no great importance in predicting primary clinical endpoints such as TTP or OS in advanced breast cancer patients. (C) 2002 Elsevier Science Ltd. All rights reserved.
|
|
| 32. |
|
|
| 33. |
- Bondeson, Lennart, et al.
(författare)
-
Michelangelo's divine goitre.
- 2003
-
Ingår i: Journal of the Royal Society of Medicine. - : SAGE Publications. - 0141-0768. ; 96:12, s. 609-611
-
Tidskriftsartikel (refereegranskat)
|
|
| 34. |
|
|
| 35. |
- Brattström, Daniel, et al.
(författare)
-
Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer
- 2003
-
Ingår i: Lung Cancer. - : Elsevier BV. - 0169-5002 .- 1872-8332. ; 43:1, s. 55-62
-
Tidskriftsartikel (refereegranskat)abstract
- Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have both been implicated to have roles in tumour angiogenesis. In the present retrospective study, serum VEGF and bFGF from patients with locally advanced non-small cell lung cancer (NSCLC) were analysed before, during and after treatment. Seventy-three patients and a total of 460 serum samples were analysed for VEGF and 443 serum samples were analysed for bFGF. Pre-treatment bFGF levels in patients with normal platelet counts, were correlated to poorer survival, P-value = 0.047. During chemotherapy, each rise of one unit bFGF corresponded to a hazard ratio of 4.06 (P=0.022). In patients with normal platelet counts, VEGF levels after radiotherapy significantly correlated to good prognosis (P=0.023), during radiotherapy VEGF levels indicated the same correlation (P=0.085). We conclude that serum VEGF and especially bFGF are of clinical interest as prognostic factors, especially in patients presenting with normal platelet counts.
|
|
| 36. |
|
|
| 37. |
- Fernandes, Oswaldo J. C. B., et al.
(författare)
-
Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer
- 2003
-
Ingår i: Acta Oncologica. - Oslo, Norway : Taylor & Francis. - 0284-186X .- 1651-226X. ; 42:4, s. 338-341
-
Tidskriftsartikel (refereegranskat)abstract
- The survival and outcome rates of 284 patients who underwent surgical treatment for non-small cell lung cancer were assessed retrospectively. Resectability rate was 94.1%, hospital mortality 3.9% (n = 11) and the mortality rates in patients who underwent pneumonectomy or lobectomy were 8.9% and 0.6%, respectively. The overall 5-year survival was 43.6%. Female gender, earlier stages of disease and a complete resection were strongly predictive for a long-term survival. Women in stage IA disease had a 5-year survival rate of 92.7%. The 5-year survival rate for patients in stages IIIA and N2 disease who underwent a complete resection was 21.9%, and 9% for those who did not undergo a complete resection. It is concluded that the best surgical results were observed in women who were operated on at an early stage of disease. A complete resection also contributed to a better outcome, even for patients in stage IIIA and N2 disease.
|
|
| 38. |
- Øra, Ingrid
(författare)
-
Approaches to Treatment of Children with Advanced Neuroblastoma
- 2003
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Children with advanced neuroblastoma are at high risk for relapse of multidrug resistant disease, despite initial response to intensive multimodality treatment. Neuroblastomas have similarities with immature neuroblasts seen during embryonic development of the sympathetic nervous system (the origin of these tumors). Chemotherapeutic drugs have various mechanisms of action and successfully treated cancer cells eventually undergo programmed cell death (apoptosis). Hence, impaired apoptotic pathways can be one explanation for drug resistance, but also represent causes for tumor initiation, progression and metastatic spread. Tumor hypoxia (low oxygen levels) due to rapid cell overgrowth and impaired vascularization is another obstacle in cancer treatment, especially recognized by radiotherapists. Recent studies have revealed that tumor hypoxia affect malignant potential of tumor cells through increased genomic instability and metastatic ability. We have identified that the embryonic transcription factor dHAND is exclusively expressed in neuroblastomas, and this protein/gene might represent a potential diagnostic marker and target for future therapy. In addition, we have found that hypoxia alters neuroblastoma cells toward an immature phenotype and we hypothesize that hypoxic cells de-differentiate and thereby retain their migration capacities, which could be an explanation for tumor progression. Hypoxic neuroblastoma cells were found resistant to cytotoxic drugs but not to mitomycin C, and we propose that this compound might be useful for targeting the hypoxic cells in the initial treatment of neuroblastoma. Arsenic trioxide, a newly re-introduced drug in the treatment of relapsed and drug-resistant acute promyelocytic leukemia, induces a p53-independent apoptotic cell death in neuroblastoma cells, which is in contrast to conventional cytotoxic agents. We suggest that arsenic trioxide could be useful in the clinical setting in the treatment of children with advanced neuroblastoma.
|
|
| 39. |
- Cunliffe, HE, et al.
(författare)
-
The gene expression response of breast cancer to growth regulators: Patterns and correlation with tumor expression profiles
- 2003
-
Ingår i: Cancer Research. - 1538-7445. ; 63:21, s. 7158-7166
-
Tidskriftsartikel (refereegranskat)abstract
- The effects of hormone and growth factor signaling on gene expression contribute significantly to breast tumorigenesis and disease progression; however, the targets of signaling networks associated with deregulated growth are not well understood. We defined the dynamic transcriptional effects elicited in MCF7, T-47D, and MDA-MB-436 breast cancer cell lines by nine regulators of growth and differentiation (17beta-estradiol, antiestrogens fulvestrant and tamoxifen, progestin R5020, antiprogestin RU486, all-trans-retinoic acid, epidermal growth factor, mitogen-activated protein/extracellular signal-regulated kinase 1/2 inhibitor U0126 and phorbol ester 12-O-tetradecanoylphorbol-13-acetate) and compared the patterns of gene regulation to published tumor expression profiles. The complex pattern of response to these agents revealed unexpected relationships between their effects, including a profound overlap in genes regulated by both steroids and epidermal growth factor, and striking overlaps between fulvestrant and all-trans-retinoic acid. Estrogen-responsive genes could be divided into two major clusters, only one of which is associated with cell proliferation. Gene ontology analysis was used to highlight functionally distinct biological responses to different mitogens. Significant correlations were identified between several clusters of drug-responsive genes and genes that discriminate estrogen receptor status or disease outcome in patient samples. The majority of estrogen receptor status discriminators were not responsive in our dataset and are therefore likely to reflect underlying differences in histogenesis and disease progression rather than growth factor signaling. This article highlights the overall impact at the gene expression level of diverse regulators of breast cancer growth and links the behavior of breast cancer cells in culture to important clinical properties of human breast tumors.
|
|
| 40. |
- Elmroth, Kerstin, 1970, et al.
(författare)
-
Chromatin- and temperature-dependent modulation of radiation-induced double-strand breaks
- 2003
-
Ingår i: International Journal of Radiation Biology. - : Informa UK Limited. - 0955-3002 .- 1362-3095. ; 79:10, s. 809-816
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: To investigate the influence of chromatin organization and scavenging capacity in relation to irradiation temperature on the induction of double-strand breaks (DSB) in structures derived from human diploid fibroblasts. Materials and methods: Agarose plugs with different chromatin structures (intact cells±wortmannin, permeabilized cells with condensed chromatin, nucleoids and DNA) were prepared and irradiated with X-rays at 2 or 37°C and lysed using two different lysis protocols (new ice-cold lysis or standard lysis at 37°C). Induction of DSB was determined by constant-field gel electrophoresis. Results: The dose-modifying factor (DMFtemp) for irradiation at 37 compared with 2°C was 0.92 in intact cells (i.e. more DSB induced at 2°C), but gradually increased to 1.5 in permeabilized cells, 2.2 in nucleoids and 2.6 in naked DNA, suggesting a role of chromatin organization for temperature modulation of DNA damage. In addition, DMFtemp was influenced by the presence of 0.1 M DMSO or 30 mM glutathione, but not by post-irradiation temperature. Conclusion: The protective effect of low temperature was correlated to the indirect effects of ionizing radiation and was not dependent on post-irradiation temperature. Reasons for a dose modifying factor <1 in intact cells are discussed.
|
|
